rdf:type |
|
lifeskim:mentions |
umls-concept:C0019169,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0026473,
umls-concept:C0038250,
umls-concept:C0042210,
umls-concept:C0205263,
umls-concept:C0229664,
umls-concept:C0237401,
umls-concept:C0332281,
umls-concept:C0376249,
umls-concept:C0441994,
umls-concept:C0871261,
umls-concept:C1332710,
umls-concept:C1367477,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
19
|
pubmed:dateCreated |
2011-4-25
|
pubmed:databankReference |
|
pubmed:abstractText |
We evaluated immunologic predictors of response to HBV vaccine administered in the presence or absence of GM-CSF in HIV infected individuals. We measured peripheral blood hematopoietic progenitor, monocyte and myeloid-derived suppressor cell (MDSC) frequencies, and expression of GMCSF receptor on monocytes and MDSCs, at baseline and 4weeks after immunization in relation to antibody response. We observed higher baseline progenitor and lower monocyte frequencies among week 16 antibody responders. Week 4 decline in MDSC frequency was associated with week 16 antibody response, while administration of GM-CSF was associated with preservation of these cells. No significant differences in GM-CSF receptor expression were observed in the presence vs. absence of GM-CSF. These findings are consistent with a positive role of progenitor cells and a potential negative role of monocytes in vaccine response. Additionally, GM-CSF augmented the preservation of peripheral blood MDSC, which may contribute to the lack of improved vaccine responses.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/AI 068634,
http://linkedlifedata.com/resource/pubmed/grant/AI 68634,
http://linkedlifedata.com/resource/pubmed/grant/AI 68636,
http://linkedlifedata.com/resource/pubmed/grant/AI038855,
http://linkedlifedata.com/resource/pubmed/grant/AI069495,
http://linkedlifedata.com/resource/pubmed/grant/AI069532,
http://linkedlifedata.com/resource/pubmed/grant/AI0801,
http://linkedlifedata.com/resource/pubmed/grant/R01 DK068361,
http://linkedlifedata.com/resource/pubmed/grant/R01 DK068361-05,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI025879-17,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI069501-06,
http://linkedlifedata.com/resource/pubmed/grant/U01 AI069532-06
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1873-2518
|
pubmed:author |
|
pubmed:copyrightInfo |
Published by Elsevier Ltd.
|
pubmed:issnType |
Electronic
|
pubmed:day |
27
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3558-63
|
pubmed:dateRevised |
2011-9-26
|
pubmed:meshHeading |
pubmed-meshheading:21397720-Antibody Formation,
pubmed-meshheading:21397720-Antigen-Presenting Cells,
pubmed-meshheading:21397720-Antigens, CD14,
pubmed-meshheading:21397720-Antigens, CD34,
pubmed-meshheading:21397720-CD4-Positive T-Lymphocytes,
pubmed-meshheading:21397720-CD8-Positive T-Lymphocytes,
pubmed-meshheading:21397720-Female,
pubmed-meshheading:21397720-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:21397720-HIV,
pubmed-meshheading:21397720-HIV Infections,
pubmed-meshheading:21397720-Hematopoietic Stem Cells,
pubmed-meshheading:21397720-Hepatitis B Antibodies,
pubmed-meshheading:21397720-Hepatitis B Vaccines,
pubmed-meshheading:21397720-Humans,
pubmed-meshheading:21397720-Male,
pubmed-meshheading:21397720-Middle Aged,
pubmed-meshheading:21397720-Monocytes,
pubmed-meshheading:21397720-Pilot Projects,
pubmed-meshheading:21397720-Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
|
pubmed:year |
2011
|
pubmed:articleTitle |
Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.
|
pubmed:affiliation |
Case Western Reserve University, Cleveland, OH 44106, USA. dda3@case.edu
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|